News & Trends - Medical Technology

ThermoFisher Scientific collaborates with Janssen to co-develop companion diagnostic for cancer

Health Industry Hub | March 16, 2020 |
[Total: 1    Average: 5/5]

MedTech News: Thermo Fisher Scientific announced it has signed an agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to co-develop a companion diagnostic (CDx) in oncology. The CDx will support clinical trial enrolments globally.

Under the agreement, Thermo Fisher Scientific will collaborate with Janssen Research & Development scientists to validate multiple biomarkers for use with Thermo Fisher’s Oncomine Dx Target Test, which will be used to identify variant-positive patients for enrolment into clinical trials focused on non-small cell lung cancer (NSCLC). Additional indications in oncology may follow as part of the agreement.

Oncomine Dx Target Test is a next-generation sequencing (NGS) assay that contains 46 cancer-related biomarkers and a workflow that features a fast turnaround time and the lowest sample requirements on the market for detection of both DNA and RNA variants.

Enhance corporate branding and boost thought leadership to attract and retain quality employees. How does your company culture and digital footprint measure up in the Australian Medical Devices industry? Get the benchmark report by contacting us.

NGS is an established method of identifying gene variants at the centre of several clinical trials or which are targeted by on-market and emerging therapies for cancer. Since its approval in 2017, Oncomine Dx Target Test has been the focus of multiple drug development and clinical trial support agreements between Thermo Fisher and international pharmaceutical companies.   

“The ability of the Oncomine Dx Target Test to rapidly detect variants of interest from very small quantities of DNA or RNA samples makes this technology ideally suited to support development programs requiring an NGS-based workflow that delivers actionable insights consistently,” said Peter Silvester, senior vice president and president of Life Sciences Solutions at Thermo Fisher Scientific. “We are confident that this approach to patient stratification helps expedite drug development initiatives which ultimately are designed to promote better health outcomes through targeted therapies.”

Register FREE and join 20,000+ industry professionals who receive the latest industry news, innovations and insights from Health Industry Hub; the only one-stop-hub connecting Australia’s Pharma, MedTech and Biotech industry professionals and its key stakeholders.

You may also like Shortage of personal protective equipment endangering health workers worldwide


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Medical

Medical News - Paramedics Association concerned over uni students being thrown in to COVID-19 frontline

Paramedics Association concerned over uni students being thrown in to COVID-19 frontline

Health Industry Hub | April 1, 2020 |

The Australian Paramedics Association NSW (APA(NSW)) has significant concerns for the safety of patients, Paramedics and university students after NSW […]

More


News & Trends - Medical Technology

MedTech News - Australia's private hospitals join the COVID-19 fight in new partnership

Australia’s private hospitals join the COVID-19 fight in new partnership

Health Industry Hub | April 1, 2020 |

A new partnership with the Commonwealth Government will guarantee the viability of Australia’s private hospital sector, ensuring its full capacity […]

More


News & Trends - Pharmaceuticals

Pharma News - Roche's adjuvant treatment PBS listed in early breast cancer

Roche’s adjuvant treatment PBS listed in early breast cancer

Health Industry Hub | April 1, 2020 |

Effective 1st April 2020, Roche’s Kadcyla is listed on the Pharmaceutical Benefits Scheme (PBS), for the adjuvant treatment of patients […]

More


Leadership & Management

Leadership & Management - Bill Gates's insights on COVID-19 global pandemic

Bill Gates’s insights on COVID-19 global pandemic

Health Industry Hub | April 1, 2020 |

In a recent TED Talk, philanthropist and Microsoft co-founder Bill Gates offers insights into the COVID-19 pandemic, discussing why testing […]

More